DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS The FDA approved Johnson & Johnson’s Tecnis PureSee EDOF IOL, the first and only EDOF lens approved without a contrast sensitivity warning. A toric version is also available for patients with 1 or more diopters of preoperative corneal astigmatism.
Professional Impact
- Tecnis PureSee is the only FDA-approved EDOF IOL matching aspheric monofocal contrast sensitivity benchmarks, removing a longstanding objection to premium lens counseling.
- 97% of patients reported no very bothersome visual disturbances, and an equal share said they would recommend the lens to others.
- The toric option extends premium IOL candidacy to astigmatic patients, consolidating refractive correction and presbyopia management in a single procedure.
- With nearly 500,000 eyes treated globally, US surgeons inherit a robust real-world safety and performance record at launch.
Action Items
- Identify astigmatic cataract patients as candidates for the toric Tecnis PureSee ahead of its US availability later in 2026.
- Update premium IOL counseling materials to reflect the contrast sensitivity and dysphotopsia profile.
- Confirm US launch timing and toric cylinder range with your J&J representative before scheduling cases.
More in Intraocular Lens (IOL)
